Drug Trial Radar · NCT07791524
Phase 2 Study of MWN109 Tablet in Participants With Overweight or Obesity
Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
255
Actual
Start
Jan 5, 2026
Primary completion
Jul 9, 2026
Study completion Jul 9, 2026
Sponsor
- Lead sponsor
- Shanghai Minwei Biotechnology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase II, multicenter, randomized, double-blind, placebo-controlled clinical trial to preliminarily evaluate the efficacy, safety, and PK of MWN109 tablets administered orally once daily in non-diabetic participants with overweight or obesity. Approximately 240 participants will be enrolled. All participants will be stratified by gender (male or female) and then randomized 1:1:1:1:1 to 5 treatment groups, with approximately 48 participants per group. All treatment groups will implement dose titration to achieve the target dose. This study consists of a screening period of up to 2 weeks, a treatment period of 20 weeks, and a follow-up period of 2 weeks, totaling 24 weeks. The primary endpoint is the percentage change in body weight compared to the baseline after 20 weeks of drug administration. The secondary endpoints include the proportions of participants with a body weight reduction of ≥5%, ≥10%, ≥15%, and ≥20% relative to the baseline after 20 weeks of treatment, as well as the change in waist circumference relative to the baseline.
Conditions
- Overweight , Obesity
Interventions
MWN109 1Drug
Administered orally, QD, 20 weeks
MWN109 2Drug
Administered orally, QD, 20 weeks
MWN109 3Drug
Administered orally, QD, 20 weeks
MWN109 4Drug
Administered orally, QD, 20 weeks
PlaceboDrug
Administered orally, QD, 20 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change in body weight compared to baseline after 20 weeks of drug administrationTime frame: Baseline, week 20
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.